$0.75
Value $91M
CATX and MRK stock compared: price, dividend, valuation and results, from SEC filings.
$0.75
Value $91M
$133.72
Value $331B
Perspective Therapeutics (CATX) has a market value of $91M and Merck & Company (MRK) $331B. Over the last year, with dividends, CATX moved -67.4% and MRK +44.8%. Dividend yield: CATX none, MRK 2.54%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
CATX$91M
MRK$331B
MRK is 3,632 times CATX
Revenue, 12 months
CATX–
MRK$67.4B
Net income, 12 months
CATX-$123M
MRK$2.5B
Operating margin
CATX–
MRK–
ROIC
CATX-43.0%
MRK3.9%
46.9 points apart
P/E
CATX–
MRK134.8
Dividend yield
CATX0.0%
MRK2.5%
2.5 points apart
5-year return
CATX-84.7%
MRK+93.0%
177.7 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
CATX-84.7%
MRK+93.0%
| Period | CATXWith dividends | MRKWith dividends |
|---|---|---|
| 1 year since November 19, 2025 | -67.4%Price -67.4% | +44.8%Price +40.7% |
| 3 years since November 20, 2023 | -70.0%-33.1% a yearPrice -70.0% | +42.7%+12.6% a yearPrice +30.2% |
| 5 years since November 19, 2021 | -84.7%-31.3% a yearPrice -84.7% | +93.0%+14.1% a yearPrice +65.7% |
| 10 years since November 21, 2016 | -86.8%-18.4% a yearPrice -86.8% | +205.2%+11.8% a yearPrice +124.9% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
CATXPerspective TherapeuticsMRKMerck & Company
| Price | $0.75 | $133.72 |
|---|---|---|
| Market value | $91M | $331B |
| Enterprise value (EV) | – | $375B |
| P/E | – | 134.8 |
| P/E, 5-year median | – | 14.8 |
| P/B | 0.3 | 7.4 |
| EV/EBIT | – | 78.7 |
| Free cash flow yield | – | 4.5% |
| Revenue, 12 months | – | $67.4B |
|---|---|---|
| Net income, 12 months | -$123M | $2.5B |
| Free cash flow, 12 months | -$139M | $14.7B |
| Earnings per share, 12 months | -$1.25 | $0.98 |
| Revenue growth, year on year | – | 1.3% |
| Revenue growth a year, past | -24.7%over 5 years | +9.4%over 5 years |
| EPS growth a year, past | – | +21.2%over 5 years |
| Gross margin | – | 71.8% |
|---|---|---|
| Operating margin | – | – |
| Net margin | – | 3.6% |
| ROIC | -43.0% | 3.9% |
| ROE | -43.4% | 5.2% |
| Cash | $202M | $9.7B |
|---|---|---|
| Total debt | $3.7M | $53.8B |
| Net debt / EBITDA | – | 5.7 |
| Interest cover | – | 2.4× |
| Dividend yield | – | 2.5% |
|---|---|---|
| Dividend per share, 12 months | – | $3.40 |
| Dividend growth a year, past | – | +5.8%over 5 years |
| Buyback yield | – | 1.5% |
| Shareholder yield | – | 4.1% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Merck & Company ($331B) is about 3,631.9 times Perspective Therapeutics ($91M), at today's prices.
Since November 21, 2016, CATX's price moved -86.8% and MRK's +124.9%. With dividends: CATX -86.8% (-18.4% a year), MRK +205.2% (+11.8% a year). Past returns do not predict future ones.
The dividend yield at today's price is none for Perspective Therapeutics and 2.54% for Merck & Company. Over the last twelve months they paid – and $3.40 per share.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.